Controlling for severity of illness in outcome studies involving infectious diseases: Impact of measurement at different time points

Infection Control and Hospital Epidemiology

Volumn 29, Issue 11, 2008, Pages 1048-1053

  Thom, Kerri A ^a   Shardell, Michelle D ^a   Osih, Regina B ^d   Schweizer, Marin L ^a   Furuno, Jon P ^a   Perencevich, Eli N ^a,b   McGregor, Jessina C ^c   Harris, Anthony D ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54949128320     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/591453     Document Type: Article

References (19)

1. Perencevich EN. Excess shock and mortality in Staphylococcus aureus related to methicillin resistance. Clin Infect Dis 2000; 31:1311-1313.
2. McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methodologies used to assess the association between appropriate antibiotic therapy and outcomes in bacteremic patients. Clin Infect Dis 2007; 45:329-337.
3. Hamilton KW, Bilker WB, Lautenbach E. Controlling for severity of illness in assessment of the association between antimicrobial-resistant infection and mortality: impact of calculation of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at different time points. Infect Control Hosp Epidemiol 2007; 28:832-836.
4. Marra AR, Bearman GM, Wenzel RP, Edmond MB. Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa. BMC Infect Dis 2006; 6:132.
5. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007; 51:839-844.
6. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97-103.
7. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-1636.
8. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535.
9. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48:4574-4581.
10. McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005; 161:483-493.
11. CLSI. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document. Wayne, PA: CLSI, 2006: M100-S16.
12. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-751.
13. Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 1998; 38:119-132.
14. Olesen B, Kolmos HJ, Orskov F, Orskov I, Gottschau A. Bacteraemia due to Escherichia coli in a Danish university hospital, 1986-1990. Scand J Infect Dis 1995; 27:253-257.
15. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
16. Watanakunakorn C, Jura J. Klebsiella bacteremia: a review of 196 episodes during a decade (1980-1989). Scand J Infect Dis 1991; 23:399-405.
17. Marra AR, Wey SB, Castelo A, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6:24.
18. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5:629-638.
19. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med 1996; 156:2121-2126.